干燥综合征患者唾液上皮细胞线粒体超微结构改变与线粒体DNA释放及模式识别受体激活相关:托法替布潜在治疗价值
本研究分析干燥综合征(SjD)患者唾液腺线粒体结构与功能改变、线粒体DNA(mtDNA)释放及炎症信号通路激活,并探讨托法替布逆转作用。结果显示SjD患者唾液腺上皮细胞胞质mtDNA释放增加,伴模式识别受体(PRR)激活增加和TFAM降低,小鼠模型类似改变可被托法替布逆转。提示线粒体改变与炎症相关,支持托法替布用于SjD患者的潜在价值。
要点
- SjD患者唾液腺上皮细胞胞质mtDNA释放增加,伴PRR激活增加和TFAM降低。
- SjD小鼠模型唾液腺出现类似线粒体超微结构改变和PRR激活增加,托法替布可逆转。
- SjD患者唾液腺电子传递链复合物活性增加,体外可受IFN-γ调节。
核心结论
- 线粒体改变与炎症相关,支持托法替布在SjD患者中的潜在应用。
研究设计与样本
- 分析SjD患者和对照的唾液腺,以及有或无托法替布治疗的SjD小鼠的唾液腺。
- 检测线粒体超微结构、胞质mtDNA、识别mtDNA的PRR水平与定位,并测定冷冻唾液腺ATP水平和耗氧率(OCR)。
- 体外评估人颌下腺细胞经IFN-γ、托法替布或两者共同孵育后的OCR。
主要发现
- SjD患者唾液腺上皮细胞胞质mtDNA释放增加,与PRR(cGAS、ZBP1、NLRP3)激活增加和TFAM降低相关。
- SjD小鼠模型唾液腺出现类似线粒体超微结构改变和PRR激活增加,托法替布可逆转这些改变。
- SjD患者唾液腺电子传递链复合物活性增加,体外可受IFN-γ调节。
- 体外托法替布在基础条件下稳定线粒体功能,抵消IFN-γ诱导的线粒体适应。
临床怎么用
- SjD患者唾液腺存在mtDNA释放和PRR激活相关的线粒体改变,托法替布可能逆转这些改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to analyse structural and functional mitochondrial alterations, the release of mitochondrial DNA (mtDNA), and the activation of inflammatory signalling pathways that can be reversed by tofacitinib in the salivary glands (SG) of patients with Sjögren's disease (SjD). METHODS: SG from patients with SjD and controls, as well as from mice with SjD treated with or without tofacitinib, were analysed. We determined the mitochondrial ultrastructure, the presence of mtDNA in the cytosol, and the levels and localisation of pattern recognition receptors (PRRs) that recognise mtDNA. The adenosine triphosphate (ATP) levels and oxygen consumption rate (OCR) were measured to evaluate mitochondrial respiration in frozen SG. We also evaluated the OCR in human submandibular gland cells incubated with interferon-gamma (IFN-γ), tofacitinib, or both. RESULTS: Increased mtDNA release into the cytosol was observed in SG epithelial cells of patients with SjD. This change was linked with increased PRR activation (cyclic GMP-AMP synthase, Z-DNA-binding protein 1, and nucleotide-binding oligomerisation domain-like receptor protein 3) and decreased mitochondrial transcription factor A (TFAM). Similar mitochondrial ultrastructural alterations and increased PRR activation were observed in the SG of the SjD mouse model. These changes were reversed by tofacitinib. Interestingly, increased activity of electron transport chain complexes was observed in SG of patients with SjD, which could be modulated by IFN-γ, as observed in vitro. We also found that tofacitinib stabilised mitochondrial function at basal conditions in vitro, counteracting the mitochondrial adaptations induced by IFN-γ. CONCLUSIONS: Taken together, these results suggest that mitochondrial alterations are linked with inflammation and support the potential use of tofacitinib in patients with SjD.
引用
- Carvajal P, Castro I, Urra F, et al. Altered mitochondrial ultrastructure in salivary epithelial cells of patients with Sjögren's disease is associated with mitochondrial DNA release and increased activation of pattern recognition receptors: potential use of tofacitinib as therapy. Ann Rheum Dis. 2026. PMID: 42000202. doi:10.1016/j.ard.2026.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。